Viking Therapeutics, Inc. (VKTX) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current |
| Current obligations | 109.66M USD | Liabilities, Current |
| Cash and equivalents | 125.75M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 375.91M USD | Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current |
| Customer receivables | (m) | |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $109.66M | $125.75M | $375.91M | (m) | (m) | (m) |
| 2026-03-31 | (m) | $106.33M | $118.12M | $484.85M | (m) | (m) | (m) |
| 2025-12-31 | (m) | $76.67M | $165.81M | $539.93M | (m) | (m) | (m) |
| 2025-09-30 | (m) | $26.07M | $100.38M | $614.19M | (m) | (m) | (m) |
| 2025-06-30 | (m) | $31.98M | $33.88M | $773.84M | (m) | (m) | (m) |
| 2025-03-31 | (m) | $19.57M | $37.94M | $813.92M | (m) | (m) | (m) |
| 2024-12-31 | (m) | $27.41M | $26.68M | $875.94M | (m) | (m) | (m) |
| 2024-09-30 | (m) | $25.68M | $50.35M | $880.09M | (m) | (m) | (m) |
| 2024-06-30 | (m) | $25.09M | $43.91M | $898.35M | (m) | (m) | (m) |
| 2024-03-31 | (m) | $32.77M | $195.58M | $767.40M | (m) | (m) | (m) |
| 2023-12-31 | (m) | $19.14M | $55.52M | $306.56M | (m) | (m) | (m) |
| 2023-09-30 | (m) | $13.40M | $37.19M | $339.06M | (m) | (m) | (m) |
| 2023-06-30 | (m) | $13.48M | $69.52M | $323.40M | (m) | (m) | (m) |
| 2023-03-31 | (m) | $15.65M | $18.36M | $117.30M | (m) | (m) | (m) |
| 2022-12-31 | (m) | $21.95M | $36.63M | $118.85M | (m) | (m) | (m) |
| 2022-09-30 | (m) | $14.06M | $29.41M | $125.61M | (m) | (m) | (m) |
| 2022-06-30 | (m) | $14.86M | $16.23M | $152.69M | (m) | (m) | (m) |
| 2022-03-31 | (m) | $11.27M | $12.45M | $172.44M | (m) | (m) | (m) |
| 2021-12-31 | (m) | $8.78M | $26.37M | $175.73M | (m) | (m) | (m) |
| 2021-09-30 | (m) | $11.35M | $11.26M | $204.87M | (m) | (m) | (m) |
| 2021-06-30 | (m) | $12.87M | $8.83M | $219.43M | (m) | (m) | (m) |
| 2021-03-31 | (m) | $12.92M | $16.80M | $224.87M | (m) | (m) | (m) |
| 2020-12-31 | (m) | $12.13M | $29.12M | $219.27M | (m) | (m) | (m) |
| 2020-09-30 | (m) | $9.71M | $3.87M | $251.43M | (m) | (m) | (m) |
| 2020-06-30 | (m) | $9.05M | $18.79M | $244.21M | (m) | (m) | (m) |
| 2020-03-31 | (m) | $8.54M | $15.26M | $253.90M | (m) | (m) | (m) |
| 2019-12-31 | (m) | $6.78M | $8.38M | $267.26M | (m) | (m) | (m) |
| 2019-09-30 | (m) | $6.19M | $30.95M | $257.12M | (m) | (m) | (m) |
| 2019-06-30 | (m) | $5.63M | $19.12M | $273.51M | (m) | (m) | (m) |
| 2019-03-31 | (m) | $4.92M | $14.34M | $284.38M | (m) | (m) | (m) |
| 2018-12-31 | (m) | $4.55M | $24.78M | $276.74M | (m) | (m) | (m) |
| 2018-09-30 | (m) | $4.74M | $169.51M | $134.66M | (m) | (m) | (m) |
| 2018-06-30 | (m) | $4.11M | $34.61M | $107.56M | (m) | (m) | (m) |
| 2018-03-31 | (m) | $6.34M | $36.36M | $41.11M | (m) | (m) | (m) |
| 2017-12-31 | (m) | $8.66M | $8.99M | $11.59M | (m) | (m) | (m) |
| 2017-09-30 | (m) | $9.61M | $2.57M | $7.27M | (m) | (m) | (m) |
| 2017-06-30 | (m) | $7.73M | $3.39M | $8.69M | (m) | (m) | (m) |
| 2017-03-31 | (m) | $3.38M | $4.36M | $7.95M | (m) | (m) | (m) |
| 2016-12-31 | (m) | $6.48M | $3.08M | $10.08M | (m) | (m) | (m) |
| 2016-09-30 | (m) | $6.08M | $3.05M | $11.56M | (m) | (m) | (m) |
| 2016-06-30 | (m) | $5.74M | $5.16M | $12.04M | (m) | (m) | (m) |
| 2016-03-31 | (m) | $1.92M | $3.96M | $7.29M | (m) | (m) | (m) |
| 2015-12-31 | (m) | $1.98M | $768.55K | $13.34M | (m) | (m) | (m) |
| 2015-09-30 | (m) | $5.72M | $2.14M | $15.35M | (m) | (m) | (m) |
| 2015-06-30 | (m) | $4.88M | $9.50M | $12.16M | (m) | (m) | (m) |
| 2015-03-31 | (m) | $27.71M | $327.01K | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | $22.52M | $755.86K | (m) | (m) | (m) | (m) |
| 2014-09-30 | (m) | (m) | $794.41K | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | $891.48K | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | $78.85K | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | (m) | $179.62K | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |